The Protein Kinase 2 Inhibitor CX-4945 Regulates Osteoclast and Osteoblast Differentiation in Vitro

Overview

Journal Mol Cells

Publisher Elsevier

Specialties Cell Biology
Molecular Biology

Date 2013 Dec 3

PMID 24293011

Citations 15

Authors

You Hwa Son

Seong Hee Moon

Jiyeon Kim

Affiliations

Soon will be listed here.

Abstract

Drug repositioning can identify new therapeutic applications for existing drugs, thus mitigating high R&D costs. The Protein kinase 2 (CK2) inhibitor CX-4945 regulates human cancer cell survival and angiogenesis. Here we found that CX-4945 significantly inhibited the RANKL-induced osteoclast differentiation, but enhanced the BMP2-induced osteoblast differentiation in a cell culture model. CX-4945 inhibited the RANKL-induced activation of TRAP and NFATc1 expression accompanied with suppression of Akt phosphorylation, but in contrast, it enhanced the BMP2-mediated ALP induction and MAPK ERK1/2 phosphorylation. CX-4945 is thus a novel drug candidate for bone-related disorders such as osteoporosis.

Citing Articles

Sex-specific trisomic Dyrk1a-related skeletal phenotypes during development in a Down syndrome model.

LaCombe J, Sloan K, Thomas J, Blackwell M, Crawford I, Bishop F Dis Model Mech. 2024; 17(9).

PMID: 39136051 PMC: 11449447. DOI: 10.1242/dmm.050914.

Sex specific emergence of trisomic -related skeletal phenotypes in the development of a Down syndrome mouse model.

LaCombe J, Sloan K, Thomas J, Blackwell M, Crawford I, Wallace J bioRxiv. 2024; .

PMID: 38826419 PMC: 11142220. DOI: 10.1101/2024.05.24.595804.

Ubiquitin-specific peptidases: Players in bone metabolism.

Shen J, Lin X, Dai F, Chen G, Lin H, Fang B Cell Prolif. 2023; 56(8):e13444.

PMID: 36883930 PMC: 10392067. DOI: 10.1111/cpr.13444.

The Role of Protein Kinase CK2 in Development and Disease Progression: A Critical Review.

Halloran D, Pandit V, Nohe A J Dev Biol. 2022; 10(3).

PMID: 35997395 PMC: 9397010. DOI: 10.3390/jdb10030031.

Targeting Sirt1, AMPK, Nrf2, CK2, and Soluble Guanylate Cyclase with Nutraceuticals: A Practical Strategy for Preserving Bone Mass.

McCarty M, Lewis Lujan L, Iloki Assanga S Int J Mol Sci. 2022; 23(9).

PMID: 35563167 PMC: 9104509. DOI: 10.3390/ijms23094776.

References

Zien P, Duncan J, Skierski J, Bretner M, Litchfield D, Shugar D . Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2. Biochim Biophys Acta. 2005; 1754(1-2):271-80. DOI: 10.1016/j.bbapap.2005.07.039. View

Matsuo K, Galson D, Zhao C, Peng L, Laplace C, Wang K . Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem. 2004; 279(25):26475-80. DOI: 10.1074/jbc.M313973200. View

Chen D, Harris M, Rossini G, Dunstan C, Dallas S, Feng J . Bone morphogenetic protein 2 (BMP-2) enhances BMP-3, BMP-4, and bone cell differentiation marker gene expression during the induction of mineralized bone matrix formation in cultures of fetal rat calvarial osteoblasts. Calcif Tissue Int. 1997; 60(3):283-90. DOI: 10.1007/s002239900230. View

Prudent R, Cochet C . New protein kinase CK2 inhibitors: jumping out of the catalytic box. Chem Biol. 2009; 16(2):112-20. DOI: 10.1016/j.chembiol.2009.01.004. View

Guerra B, Issinger O . Protein kinase CK2 and its role in cellular proliferation, development and pathology. Electrophoresis. 1999; 20(2):391-408. DOI: 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N. View

Gyenis L, Turowec J, Bretner M, Litchfield D . Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2. Biochim Biophys Acta. 2013; 1834(7):1352-8. DOI: 10.1016/j.bbapap.2013.02.006. View

Son Y, Song J, Kim S, Kim J . Pharmacokinetic characterization of CK2 inhibitor CX-4945. Arch Pharm Res. 2013; 36(7):840-5. DOI: 10.1007/s12272-013-0103-9. View

Booth B, Zemmel R . Prospects for productivity. Nat Rev Drug Discov. 2004; 3(5):451-6. DOI: 10.1038/nrd1384. View

Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K . RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 2002; 416(6882):744-9. DOI: 10.1038/416744a. View

10.

Sarno S, Reddy H, Meggio F, Ruzzene M, DAVIES S, Donella-Deana A . Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett. 2001; 496(1):44-8. DOI: 10.1016/s0014-5793(01)02404-8. View

11.

Pierre F, Chua P, OBrien S, Siddiqui-Jain A, Bourbon P, Haddach M . Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J Med Chem. 2010; 54(2):635-54. DOI: 10.1021/jm101251q. View

12.

Grigoriadis A, Wang Z, Cecchini M, Hofstetter W, Felix R, Fleisch H . c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science. 1994; 266(5184):443-8. DOI: 10.1126/science.7939685. View

13.

Allende J, Allende C . Protein kinases. 4. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation. FASEB J. 1995; 9(5):313-23. DOI: 10.1096/fasebj.9.5.7896000. View

14.

Pierre F, Chua P, OBrien S, Siddiqui-Jain A, Bourbon P, Haddach M . Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol Cell Biochem. 2011; 356(1-2):37-43. DOI: 10.1007/s11010-011-0956-5. View

15.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

16.

Franceschi R, Iyer B . Relationship between collagen synthesis and expression of the osteoblast phenotype in MC3T3-E1 cells. J Bone Miner Res. 1992; 7(2):235-46. DOI: 10.1002/jbmr.5650070216. View

17.

Asagiri M, Takayanagi H . The molecular understanding of osteoclast differentiation. Bone. 2006; 40(2):251-64. DOI: 10.1016/j.bone.2006.09.023. View

18.

Ashburn T, Thor K . Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-83. DOI: 10.1038/nrd1468. View

19.

Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F . Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ. 2005; 12(6):668-77. DOI: 10.1038/sj.cdd.4401604. View

20.

Kim H, Kim S . Tanshinone IIA enhances BMP-2-stimulated commitment of C2C12 cells into osteoblasts via p38 activation. Amino Acids. 2010; 39(5):1217-26. DOI: 10.1007/s00726-010-0557-8. View